113 related articles for article (PubMed ID: 9214677)
1. Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics.
Minami H; Ando Y; Saka H; Shimokata K
J Natl Cancer Inst; 1997 Jul; 89(13):968-70. PubMed ID: 9214677
[No Abstract] [Full Text] [Related]
2. Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics.
Sridhara R
J Natl Cancer Inst; 1997 Oct; 89(20):1546-7. PubMed ID: 9337355
[No Abstract] [Full Text] [Related]
3. Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing.
Ando Y; Minami H; Saka H; Ando M; Sakai S; Shimokata K
Br J Cancer; 1997; 76(8):1067-71. PubMed ID: 9376268
[TBL] [Abstract][Full Text] [Related]
4. Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity.
Bretagne M; Jouinot A; Durand JP; Huillard O; Boudou Rouquette P; Tlemsani C; Arrondeau J; Sarfati G; Goldwasser F; Alexandre J
Cancer Chemother Pharmacol; 2017 Jul; 80(1):45-53. PubMed ID: 28508095
[TBL] [Abstract][Full Text] [Related]
5. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
[TBL] [Abstract][Full Text] [Related]
6. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
Huitema AD; Mathôt RA; Tibben MM; Schellens JH; Rodenhuis S; Beijnen JH
Clin Pharmacol Ther; 2000 Jun; 67(6):621-30. PubMed ID: 10872644
[TBL] [Abstract][Full Text] [Related]
7. Flat dosing of carboplatin is justified in adult patients with normal renal function.
Ekhart C; de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2006 Nov; 12(21):6502-8. PubMed ID: 17085665
[TBL] [Abstract][Full Text] [Related]
8. Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics.
Fujiwara Y; Takahashi T; Yamakido M; Ohune T; Tsuya T; Egorin MJ
J Natl Cancer Inst; 1997 Feb; 89(3):260-2. PubMed ID: 9017009
[No Abstract] [Full Text] [Related]
9. Carboplatin dosing in children: calculation by different formulae.
Würthwein G; Krefeld B; Gerss J; Boos J
Onkologie; 2011; 34(1-2):16-22. PubMed ID: 21346380
[TBL] [Abstract][Full Text] [Related]
10. Carboplatin dosing for adult Japanese patients.
Ando Y; Shimokata T; Yasuda Y; Hasegawa Y
Nagoya J Med Sci; 2014 Feb; 76(1-2):1-9. PubMed ID: 25129986
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies.
de Lemos ML; Hsieh T; Hamata L; Levin A; Swenerton K; Djurdjev O; Vu T; Hu F; Conklin J; Malfair Taylor SC
Gynecol Oncol; 2006 Dec; 103(3):1063-9. PubMed ID: 16875719
[TBL] [Abstract][Full Text] [Related]
12. Difficulties in carboplatin dosage due to different methods of serum creatinine determination.
Groth G; Gatzemeier U
Lung Cancer; 2002 Oct; 38(1):97-8. PubMed ID: 12367800
[No Abstract] [Full Text] [Related]
13. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
Ekhart C; Rodenhuis S; Schellens JH; Beijnen JH; Huitema AD
Cancer Chemother Pharmacol; 2009 Jun; 64(1):115-22. PubMed ID: 18989671
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer.
Shimokata T; Ando Y; Yasuda Y; Hamada A; Kawada K; Saito H; Matsuo S; Kondo M; Imaizumi K; Hasegawa Y
Cancer Sci; 2010 Dec; 101(12):2601-5. PubMed ID: 20860621
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of two dose individualisation methods for carboplatin.
Desoize B; Dufour R; Urien S; Kaltenbach M; Colin P
Anticancer Res; 1996; 16(4A):2073-8. PubMed ID: 8712745
[TBL] [Abstract][Full Text] [Related]
16. How to predict carboplatin clearance from standard morphological and biological characteristics in obese patients.
Bénézet S; Guimbaud R; Chatelut E; Chevreau C; Bugat R; Canal P
Ann Oncol; 1997 Jun; 8(6):607-9. PubMed ID: 9261532
[TBL] [Abstract][Full Text] [Related]
17. Extension of the Calvert formula to patients with severe renal insufficiency.
Oguri T; Shimokata T; Ito I; Yasuda Y; Sassa N; Nishiyama M; Hamada A; Hasegawa Y; Ando Y
Cancer Chemother Pharmacol; 2015 Jul; 76(1):53-9. PubMed ID: 25957958
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of carboplatin in children.
Chatelut E; Boddy AV; Peng B; Rubie H; Lavit M; Dezeuze A; Pearson AD; Roché H; Robert A; Newell DR; Canal P
Clin Pharmacol Ther; 1996 Apr; 59(4):436-43. PubMed ID: 8612389
[TBL] [Abstract][Full Text] [Related]
19. Current dilemmas in carboplatin dosing.
Ratain MJ
Clin Adv Hematol Oncol; 2011 Mar; 9(3):237-8. PubMed ID: 21475131
[No Abstract] [Full Text] [Related]
20. Prediction of carboplatin clearance from standard morphological and biological patient characteristics.
Chatelut E; Canal P; Brunner V; Chevreau C; Pujol A; Boneu A; Roché H; Houin G; Bugat R
J Natl Cancer Inst; 1995 Apr; 87(8):573-80. PubMed ID: 7752255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]